MXene-based CRISPR/Cas9 nanoplatform targeting FABP5 for ROS amplification and synergistic photothermal/photodynamic therapy of cervical cancer
A nanoparticle-gene therapy approach achieved strong tumor control in cervical cancer models, though human testing is needed.
This preclinical study develops a MXene-CRISPR/Cas9 nanoplatform that silences FABP5 to disrupt antioxidant defenses while using photothermal/photodynamic effects to amplify ROS, achieving ~96% tumor inhibition in cervical cancer models. The approach is promising but remains early-stage preclinical with no human validation.
What the study was
- Study design
- Preclinical (in vitro and in vivo xenograft)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Journal of Nanobiotechnology
Why it surfaced
Innovative gene-editing + phototherapy combination; non-human cap applies (preclinical only, triage_score capped at 4).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.